Elective coronary revascularization, an iatrogenic form of acute coronary syndrome: How can clinicians reduce the risks?

American Heart Journal

Volumn 148, Issue 3, 2004, Pages 371-377

  Mukherjee, Debabrata ^a   Oz, Mehmet ^b   Prager, Richard ^a   Eagle, Kim A ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; PROTEIN KINASE; QUINAPRIL; RAMIPRIL; THROMBIN INHIBITOR; TROPONIN C;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; DIAGNOSTIC PROCEDURE; DISEASE MARKER; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LABORATORY TEST; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

EID: 4644253763     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.04.012     Document Type: Article

References (56)

1. Chaitman B.R., Alderman E.L., Sheffield L.T., et al. Use of survival analysis to determine the clinical significance of new Q waves after coronary bypass surgery. Circulation. 67:1983;302-309
2. Schaff H.V., Gersh B.J., Fisher L.D., et al. Detrimental effect of perioperative myocardial infarction on late survival after coronary artery bypass report from the Coronary Artery Surgery Study - CASS. J Thorac Cardiovasc Surg. 88:1984;972-981
3. Brener S.J., Lytle B.W., Schneider J.P., et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol. 40:2002;1961-1967
4. Costa M.A., Carere R.G., Lichtenstein S.V., et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation. 104:2001;2689-2693
5. Steuer J., Horte L.G., Lindahl B., et al. Impact of perioperative myocardial injury on early and long-term outcome after coronary artery bypass grafting. Eur Heart J. 23:2002;1219-1227
6. Klatte K., Chaitman B.R., Theroux P., et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release results from the GUARDIAN trial. J Am Coll Cardiol. 38:2001;1070-1077
7. Januzzi J.L., Lewandrowski K., MacGillivray T.E., et al. A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll Cardiol. 39:2002;1518-1523
8. Rasmussen C., Thiis J.J., Clemmensen P., et al. Significance and management of early graft failure after coronary artery bypass grafting feasibility and results of acute angiography and re-re-vascularization. Eur J Cardiothorac Surg. 12:1997;847-852
9. Fuchs S., Kornowski R., Mehran R., et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol. 85:2000;1077-1082
10. Kugelmass A.D., Cohen D.J., Moscucci M., et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol. 74:1994;748-754
11. Abdelmeguid A.E., Topol E.J., Whitlow P.L., et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 94:1996;1528-1536
12. Califf R.M., Abdelmeguid A.E., Kuntz R.E., et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 31:1998;241-251
13. Mehran R., Dangas G., Mintz G.S., et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions intravascular ultrasound study of 2256 patients. Circulation. 101:2000;604-610
14. Ellis S.G., Chew D., Chan A., et al. Death following creatine kinase-MB elevation after coronary intervention identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 106:2002;1205-1210
15. Ioannidis J., Karvouni E., Katritsis D. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 42:2003;1406-1411
16. Kini A.S., Lee P., Marmur J.D., et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 93:2004;18-23
17. Nallamothu B.K., Chetcuti S., Mukherjee D., et al. Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol. 91:2003;1272-1274
18. Ricciardi M.J., Davidson C.J., Gubernikoff G., et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J. 145:2003;522-528
19. Kizer J.R., Muttrej M.R., Matthai W.H., et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J. 24:2003;1314-1322
20. Liu P.Y., Li Y.H., Tsai W.C., et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J. 24:2003;1824-1832
21. Ricciardi M.J., Wu E., Davidson C.J., et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation. 103:2001;2780-2783
22. Mangano D.T. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 347:2002;1309-1317
23. Bhatt D.L., Chew D.P., Hirsch A.T., et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 103:2001;363-368
24. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997;336:153-62
25. Ferguson T.B. Jr, Coombs L.P., Peterson E.D. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA. 287:2002;2221-2227
26. Oosterga M., Voors A.A., Pinto Y.M., et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol. 87:2001;542-546
27. Kjoller-Hansen L., Steffensen R., Grande P. Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular function and no clinical heart failure. J Am Coll Cardiol. 37:2001;1214-1220
28. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153
29. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 362:2003;782-788
30. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 107:2003;149-158
31. Topol E.J., Lincoff A.M., Kereiakes D.J., et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 113:2002;1-6
32. Kong D.F., Hasselblad V., Harrington R.A., et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 92:2003;651-655
33. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention REPLACE-2 randomized trial. JAMA. 289:2003;853-863
34. Chan A.W., Bhatt D.L., Chew D.P., et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 105:2002;691-696
35. Chan A.W., Quinn M.J., Bhatt D.L., et al. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol. 40:2002;669-675
36. Steinhubl S.R., Berger P.B., Mann J.T. III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial. JAMA. 288:2002;2411-2420
37. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention the PCI-CURE study. Lancet. 358:2001;527-533
38. Gum P.A., Kottke-Marchant K., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 41:2003;961-965
39. Gaudino M., Nasso G., Zamparelli R., et al. Inflammatory and fibrinolytic activation after coronary artery bypass with extracorporeal circulation [in Italian]. Ital Heart J. 3:2002;646-651
40. Almagor M., Keren A., Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. Am Heart J. 145:2003;248-253
41. Topol E.J., Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 101:2000;570-580
42. Willerson J., Cohen L., Maser A. Pathophysiology and clinical recognition. Willerson J., Cohn J. Cardiovascular medicine. 1995;333-365 Churchill Livingston, New York
43. Lefkovits J., Holmes D.R., Califf R.M., et al. Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary Angioplasty Versus Excisional Atherectomy Trial. Circulation. 92:1995;734-740
44. Sharma S.K., Kini A., Marmur J.D., et al. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention benefit is extended to improvement in intermediate-term survival. Circulation. 102:2000;166-172
45. DeFoe G.R., Ross C.S., Olmstead E.M., et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 71:2001;769-776
46. Toyofyuku M., Imazu M., Sumii K., et al. Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis. 160:2002;339-344
47. Chang P.P., Sussman M.S., Conte J.V., et al. Postoperative ventricular function and cardiac enzymes after on-pump versus off-pump CABG surgery. Am J Cardiol. 89:2002;1107-1110
48. Kim K.B., Kang C.H., Chang W.I., et al. Off-pump coronary artery bypass with complete avoidance of aortic manipulation. Ann Thorac Surg. 74:2002;S1377-1382
49. Ascione R., Lloyd C.T., Gomes W.J., et al. Beating versus arrested heart revascularization evaluation of myocardial function in a prospective randomized study. Eur J Cardiothorac Surg. 15:1999;685-690
50. Krejca M., Skiba J., Szmagala P., et al. Cardiac troponin T release during coronary surgery using intermittent cross-clamp with fibrillation, on-pump and off-pump beating heart. Eur J Cardiothorac Surg. 16:1999;337-341
51. Puskas J.D., Williams W.H., Duke P.G., et al. Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg. 125:2003;797-808
52. Dewey T.M., Magee M.J., Acuff T., et al. Beating heart surgery reduces mortality in the reoperative bypass patient. Heart Surg Forum. 5:(Suppl 4):2002;S301-316
53. Nathoe H.M., van Dijk D., Jansen E.W., et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med. 348:2003;394-402
54. Fillinger M.P., Surgenor S.D., Hartman G.S., et al. The association between heart rate and in-hospital mortality after coronary artery bypass graft surgery. Anesth Analg. 95:2002;1483-1488
55. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 350:2004;1495-1504
56. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis a randomized controlled trial. JAMA. 291:2004;1071-1080